[MRCB] YoY Annualized Quarter Result on 31-Dec-2022 [#4]

Stock
[MRCB] MALAYSIAN RESOURCES CORPORATION BERHAD
Announcement Date
20-Feb-2023
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2022
Quarter
31-Dec-2022 [#4]
Profit Trend
QoQ- -6.16%
YoY- 309.56%
Quarter Report
Latest QR
Upcoming QR
MRCB's Result
MRCB's Financial Summary
View:
Show?
Annualized Quarter Result
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Revenue 2,514,113 3,205,061 1,448,450 1,199,484 1,319,393 1,870,705 2,823,651 -1.91%
PBT 134,249 154,336 61,303 -152,916 52,955 122,987 247,333 -9.67%
Tax -33,163 -100,789 -54,585 -22,950 -34,263 -20,332 -65,525 -10.72%
NP 101,086 53,547 6,718 -175,866 18,692 102,655 181,808 -9.31%
-
NP to SH 101,031 64,849 15,834 -176,143 23,739 101,167 167,575 -8.08%
-
Tax Rate 24.70% 65.30% 89.04% - 64.70% 16.53% 26.49% -
Total Cost 2,413,027 3,151,514 1,441,732 1,375,350 1,300,701 1,768,050 2,641,843 -1.49%
-
Net Worth 4,592,599 4,530,054 4,512,184 4,579,703 4,791,482 4,829,850 2,411,814 11.32%
Dividend
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Div 44,675 44,675 44,675 44,120 44,120 76,838 38,369 2.56%
Div Payout % 44.22% 68.89% 282.15% 0.00% 185.86% 75.95% 22.90% -
Equity
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Net Worth 4,592,599 4,530,054 4,512,184 4,579,703 4,791,482 4,829,850 2,411,814 11.32%
NOSH 4,467,509 4,467,509 4,467,509 4,412,046 4,412,046 4,395,052 4,386,746 0.30%
Ratio Analysis
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
NP Margin 4.02% 1.67% 0.46% -14.66% 1.42% 5.49% 6.44% -
ROE 2.20% 1.43% 0.35% -3.85% 0.50% 2.09% 6.95% -
Per Share
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 56.28 71.74 32.42 27.19 29.90 42.61 128.78 -12.88%
EPS 2.26 1.45 0.36 -3.99 0.54 2.30 6.56 -16.26%
DPS 1.00 1.00 1.00 1.00 1.00 1.75 1.75 -8.90%
NAPS 1.028 1.014 1.01 1.038 1.086 1.10 1.10 -1.12%
Adjusted Per Share Value based on latest NOSH - 4,467,509
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 56.76 72.36 32.70 27.08 29.79 42.23 63.75 -1.91%
EPS 2.28 1.46 0.36 -3.98 0.54 2.28 3.78 -8.07%
DPS 1.01 1.01 1.01 1.00 1.00 1.73 0.87 2.51%
NAPS 1.0368 1.0227 1.0187 1.0339 1.0817 1.0904 0.5445 11.32%
Price Multiplier on Financial Quarter End Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 29/12/23 30/12/22 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 -
Price 0.445 0.295 0.355 0.475 0.73 0.615 1.12 -
P/RPS 0.79 0.41 1.09 1.75 2.44 1.44 0.87 -1.59%
P/EPS 19.68 20.32 100.16 -11.90 135.68 26.69 14.65 5.04%
EY 5.08 4.92 1.00 -8.40 0.74 3.75 6.82 -4.78%
DY 2.25 3.39 2.82 2.11 1.37 2.85 1.56 6.29%
P/NAPS 0.43 0.29 0.35 0.46 0.67 0.56 1.02 -13.40%
Price Multiplier on Announcement Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 29/02/24 20/02/23 28/02/22 25/02/21 26/02/20 26/02/19 28/02/18 -
Price 0.585 0.325 0.355 0.415 0.66 0.80 1.08 -
P/RPS 1.04 0.45 1.09 1.53 2.21 1.88 0.84 3.62%
P/EPS 25.87 22.39 100.16 -10.39 122.67 34.72 14.13 10.60%
EY 3.87 4.47 1.00 -9.62 0.82 2.88 7.08 -9.57%
DY 1.71 3.08 2.82 2.41 1.52 2.19 1.62 0.90%
P/NAPS 0.57 0.32 0.35 0.40 0.61 0.73 0.98 -8.63%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment